Skip to main content
. 2016 Jun 9;7(29):45249–45262. doi: 10.18632/oncotarget.9932

Figure 4. Pyrvinium pamoate interferes with the Chk1/Cdk1 pathway.

Figure 4

(A and B) Pyrvinium pamoate suppresses Chk1 and activated Cdk1 in dose-dependent (A) and time-dependent (B) manners. (C) Cdk1 inhibition rescues pyrvinium pamoate-mediated HuR cytoplasmic translocation. 5637 cells were treated with doxorubicin (360 nmol/L) for 12 h, followed by treatments with pyrvinium pamoate (100 nmol/L) and/or AZD5438 (10 μmol/L) for an additional 6 h, respectively. (D) HuR mutation at S202 site affects pyrvinium pamoate-mediated inhibition of HuR cytoplasmic translocation. Non, non-treatment; Dox, doxorubicin; PP, pyrvinium pamoate; AZD, AZD5438.